Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.
Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).
The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.
Ninety percent of all vaccine preventable deaths occur in those 65 and older, including residents in nursing homes, according to highlighted studies in the Pennsylvania Patient Safety Authority's 2009 December Patient Safety Advisory.
Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children.
Nearly 100 leading global health organizations from around the world joined forces to recognize the first-annual World Pneumonia Day on November 2 and urge governments to take steps to fight pneumonia, the world’s leading killer of young children.
Wednesday's release of the WHO, UNICEF and the World Bank joint report on childhood vaccines highlighted gains in recent global vaccination campaigns and also found that nearly 24 million infants worldwide don't get the recommended first-year vaccination.
Reversing a downward trend, immunization rates are now at their highest ever and vaccine development worldwide is booming, according to a new assessment released today by the World Health Organization (WHO), UNICEF and the World Bank.
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.
GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company's vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.
New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.
"Each year 1.2 million children under age 5 die from Streptococcus pneumoniae and Haemophilus influenzae B or Hib," which cause pneumococcal disease and are preventable with vaccines, according to studies published Thursday in the journal Lancet, Reuters reports.
New World Health Organization data to be published in this week's edition of The Lancet will shed new light on two leading causes of pneumonia, the world’s leading killer of children under age 5, both globally and within specific countries.
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
During a recent three-day Asian Vaccine Conference, health experts appealed to countries to add "under-utilised vaccines such as those of pneumococcal, haemophilus influenzae type-b (Hib), and rotavirus" into national immunization programs, the Nation reports.
The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.
The Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) is calling for the pneumonia vaccine to become an official part of India's required list of immunizations, the Times of India reports.
A new trial has found that pneumococcal vaccine is effective in preventing severe pneumonia, the leading cause of death among children in developing countries. Co-ordinated by the National Institute for Health and Welfare (THL) between 2000 and 2004, a large scale efficacy trial - first of its kind in Asia - was carried out in the Philippines to investigate the effect of an investigational pneumococcal vaccine.
The Wall Street Journal examines a $1.5 billion program supported by Italy, the U.K., Canada, Russia, Norway and the Bill & Melinda Gates Foundation that hopes "to encourage pharmaceutical companies to develop vaccines for diseases common to poor countries," which is expected to be announced Friday "on the sidelines of a meeting of top finance officials from the Group of Eight major industrial powers."
Drug maker GlaxoSmithKline (GSK) on Tuesday opened a $600 million plant in Singapore that is slated to begin producing vaccines to fight pneumonia-causing bacteria in 2011, Reuters reports.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.